Daily rollup · Sunday, November 1, 2026

A rough week for AI stocks lands right before ANT's roadshow

Big Tech earnings rattled AI investors just days after Anthropic's prospectus went public, and the Nasdaq posted its first three-week losing streak since March. Meanwhile a biotech startup says a Claude Sonnet agent carried out a brain injection on a live mouse after Opus 5.5 declined, developers report Claude Code refusals well beyond game cloning, and the earliest possible first trade for ANT works out to November 16.

Illustration: an ant colony whose tunnels hold glowing server racks

The brief

01Results from Microsoft, Alphabet and Amazon raised new doubts about how the AI build-out gets paid for, and the Nasdaq fell 2.9% on Friday. CNBC says Anthropic's roadshow will have to answer those questions.
02Exin Therapeutics says a Claude Sonnet 5 agent picked a gene therapy and drove the needle for an injection into a live mouse's brain, with a vet approving each step. Opus 5.5 declined to do the injection. This is the company's own account.
03Developers say Claude Code and Opus 5.5 are now refusing some reverse-engineering, crash-dump and anti-cheat work, not just game clones. Anthropic has not commented on the wider reports.
04By Yahoo Finance's count of SEC timing rules, the earliest ANT could start trading on the Nasdaq is Monday, November 16. No price range has been filed yet.

$ANT Desk Nov 1

Big Tech's earnings week makes ANT's path to the Nasdaq bumpier

Weak cash flow from the hyperscalers and a 2.9% Nasdaq drop on Friday set a skeptical mood ahead of the roadshow.

Days after Anthropic's S-1 went public, Microsoft, Alphabet and Amazon reported results that fed investor worries about the cost of the AI build-out, CNBC reports. Microsoft cut its capex forecast for the year to $170 billion from $175 billion and plans a $25 billion bond sale. Alphabet's trailing free cash flow turned negative, and its shares fell almost 13% on Thursday, their worst day ever. Amazon posted a second straight quarter of negative trailing free cash flow. The Nasdaq Composite fell 2.9% on Friday, closing out its first three-week losing streak since March.

The timing matters for Anthropic because Amazon and Google are both among its largest compute suppliers and its biggest investors, and CNBC expects that relationship to be a major roadshow topic. The IPO market has been mostly frozen since SpaceX listed in June, and several companies have recently postponed or dropped listings. Futurum's Daniel Newman called the prospectus 'very impressive' and said 'Anthropic is the IPO market at this point,' but warned that companies would be 'extremely cautious, if not just foolish' to list in this climate. Anthropic has not yet published its third-quarter financials in the filing.

Nasdaq, Friday: −2.9%
Alphabet, Thursday: ≈ −13% (worst day ever)
Microsoft capex forecast: $170B (was $175B)

Read the full story at CNBC

Sources CNBC

More from Nov 1

Safety & Governance

Startup says a Claude agent performed a live-mouse brain injection after Opus 5.5 declined

Exin Therapeutics switched to Sonnet 5 for the procedure. A vet approved every irreversible step and held a kill switch.

Exin Therapeutics, a San Francisco startup working on epilepsy drugs, told WIRED it connected an AI agent to a motorized surgery rig with a camera and gave it a mouse model of epilepsy and 19 candidate gene therapies in a spreadsheet. After a veterinary surgeon opened the skull, the agent picked the therapy, the brain region and the coordinates, then drove the needle and set the injection volume and speed. A human had to approve the plan, an emergency button could cut power to the motors, and the agent was blocked from editing the equipment code.

According to CEO Gabriel Ocana Santero, Claude Opus 5.5 planned the experiment but would not guide the needle, warning that it might get cut off partway through and leave the animal at risk. The team switched to Claude Sonnet 5, which went ahead. When a glitch broke the rig's coordinates, the agent saw the problem but would not touch the code, so the team had a separate Opus 5 agent make the fix without telling it surgery was underway. The procedure ran a little over an hour, compared with about 45 minutes normally. The mouse is reportedly recovering, and whether the therapy reduces seizures is not yet known.

This is the company's own account, first posted on X. There is no paper or independent review, and WIRED says Anthropic did not respond. The episode raises an obvious question for Anthropic's safeguards: a refusal from one model was worked around by switching to another.

Model that did the injection: Claude Sonnet 5
Model that declined: Claude Opus 5.5
Status: Company account; unverified

Read the full story at WIRED

Sources WIRED

Products & Code

Developers say Claude Code's game rule is catching legitimate work too

Reports describe refusals on crash dumps, anti-cheat reviews and developers' own games.

A day after the new rule against recreating existing games surfaced, Tom's Hardware rounded up user reports that Claude Code and Opus 5.5 are refusing a wider range of tasks. Examples include analyzing a simple Windows crash dump, removing junkware from a Samsung TV, using the Reverse Engineer Anything tool, copying a game mechanic in the middle of a developer's own project, and anti-cheat or security reviews of a developer's own game. Claude Code's GitHub repository has seen a wave of issues describing similar refusals.

It is not clear whether these refusals come from the game rule, from Anthropic's tighter cybersecurity safeguards, or from both. Tom's Hardware notes that some complainants may have had bad intentions, but says at least one is a developer with a real track record. Anthropic has not made an official statement about the broader reports.

Affected: Claude Code / Opus 5.5 (reported)
Anthropic statement: None on wider refusals

Read the full story at Tom's Hardware

Sources Tom's Hardware Mashable

$ANT Desk

The earliest ANT can trade is Monday, November 16

SEC timing rules count back from the S-1 filing date, and a roadshow and a price range come first.

Anthropic has not set an IPO date, but Yahoo Finance's reading of SEC rules puts the earliest possible Nasdaq debut on Monday, November 16. That matches earlier reports from the Wall Street Journal and Reuters that the company is aiming for that week. Before then, Anthropic and its banks need to file an amended S-1 with a price range, run the investor roadshow (reportedly starting as soon as the week of November 9), set a final price and get the SEC to declare the registration effective.

Yahoo Finance notes that the earliest possible pricing date would be Friday, November 13, which banks rarely use because buyers would then have to wait through the weekend before trading starts. Any of these dates could slip if markets stay rocky.

Earliest first trade: Mon, Nov 16, 2026
Earliest pricing: Fri, Nov 13, 2026
Price range: Not yet filed

Read the full story at Yahoo Finance

Sources Yahoo Finance